| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 1.35 | 27.0% |
| Total Income | 1.35 | 27.0% |
| Expenditure | 4.97 | 10.9% |
| PBT | -3.63 | 37.0% |
| Net Profit | -3.63 | 36.5% |
| OPM | — | |
| NPM | — | |
| EPS | -0.81 | 406.3% |
bioAffinity Technologies Reports Q1 2026 Results; CyPath® Lung Sales Up 146%
08 May 2026 · 8 May, 6:06 pm
Summary
bioAffinity Technologies reported financial results for the first quarter ended March 31, 2026. CyPath® Lung unit sales increased by 146% year-over-year, and testing revenue increased by approximately 114% to $361,000. Total consolidated revenue decreased by approximately 27% to $1.4 million, resulting from the discontinuation of certain unprofitable pathology services. The company launched a large-scale longitudinal clinical trial to further validate CyPath® Lung performance.
Key Highlights
- 1
CyPath® Lung unit sales increased 146% year-over-year in the first quarter of 2026.
- 2
CyPath® Lung testing revenue increased approximately 114% to $361,000, compared to $169,000 in the first quarter of 2025.
- 3
Total consolidated revenue decreased approximately 27% to $1.4 million, compared to $1.9 million for the first quarter of 2025, due to the discontinuation of certain unprofitable pathology services.
- 4
The number of physician offices and clinics ordering CyPath® Lung increased 69% from first quarter 2025 to the same period in 2026.
- 5
The company launched a large-scale longitudinal clinical trial partially funded by the U.S. Department of Defense to further validate CyPath® Lung performance.
Management Comments
Maria Zannes
Our first quarter results demonstrate continued momentum for CyPath® Lung in the marketplace. As more and more physicians adopt CyPath® Lung and share their experiences with peers, we see the opportunity to expand our commercial reach and bridge the diagnostic gap between imaging and invasive procedures, especially when dealing with indeterminate nodules in high-risk patients. Physicians continue to share their case studies in which CyPath® Lung has identified lung cancer as early as Stage 1A when it is most treatable and conversely in which a negative CyPath® Lung result helped avoid unnecessary invasive procedures. We believe the growing number of case studies and our longitudinal clinical trial, supported by leading military and VA institutions, will lead to broader adoption of CyPath® Lung as part of the standard of care. We are uniquely positioned to fulfill the need for an accurate, noninvasive diagnostic for lung cancer, particularly when imaging and risk models are inconclusive or turn out to be wrong. The remainder of 2026 will be focused on scaling commercial execution, expanding into new geographic markets, and driving increased utilization of CyPath® Lung through continued physician engagement while also leveraging our flow cytometry and AI platform to advance our pipeline of diagnostics for serious or life-threatening lung diseases.
Informational and educational content only. Not investment advice.